GORE-TEX Military Fabrics

Streamlight Continues Support for Breast Cancer Research With $20,000 Donation

Company Marks 14 Years of Partnership with Breast Cancer Research Foundation®

EAGLEVILLE, PA, November 20, 2024 – Streamlight®Inc., a leading provider of high-performance lighting, announced its continued commitment to the Breast Cancer Research Foundation® (BCRF) with a $20,000 donation to support breast cancer research and prevention. Each year, Streamlight contributes proceeds from sales of specially marked pink lights to BCRF, reflecting the company’s commitment to improve outcomes and save lives for those impacted by breast cancer.

As the largest private funder of breast cancer research worldwide, BCRF recently announced its commitment of $70.3 million to support global breast cancer research in 2024-2025, awarding grants to over 260 researchers across 15 countries.

According to BCRF, a woman in the US is diagnosed with breast cancer every two minutes, with over 42,000 women and 530 men projected to die from the disease this year. Research has significantly improved outcomes, with breast cancer mortality rates down 44% since 1989.

Streamlight donated the proceeds from sales of its pink Nano Light® keychain light, pink Siege® AA ultra-compact lantern, and pink Strion® LED tactical light. For each of the lights, Streamlight donates $1.00, $2.00, and $5.00, respectively. 

“Our support for the Breast Cancer Research Foundation is a cause very close to our hearts,” said Streamlight Chief Revenue Officer Michael F. Dineen. “With survivors among our employees, we are honored to contribute to BCRF’s groundbreaking work. Our pink lights allow us to not only fundraise but also raise awareness for this important cause.”

Streamlight first introduced its line of pink lights in 2008 and has since maintained its dedication to helping BCRF advance research and improve survival rates for those impacted by breast cancer.

To learn more about Streamlight’s pink lights and other Lights for a Cause, please click here.

Leave a Reply